Pressure Ulcers - Pipeline Review, H2 2017 - Product Image

Pressure Ulcers - Pipeline Review, H2 2017

  • ID: 4337647
  • Report
  • 37 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • EyeGene Inc
  • Izun Pharmaceuticals Corp
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • RMB-Research GmbH
  • MORE
Pressure Ulcers - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers - Pipeline Review, H2 2017, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape.

Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Pressure Ulcers - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pressure Ulcers (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 3, 1 and 4 respectively.

Pressure Ulcers (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pressure Ulcers (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pressure Ulcers (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pressure Ulcers (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pressure Ulcers (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pressure Ulcers (Dermatology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pressure Ulcers (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pressure Ulcers (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • EyeGene Inc
  • Izun Pharmaceuticals Corp
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • RMB-Research GmbH
  • MORE
Introduction

Pressure Ulcers - Overview

Pressure Ulcers - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pressure Ulcers - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pressure Ulcers - Companies Involved in Therapeutics Development

EyeGene Inc

Izun Pharmaceuticals Corp

MediWound Ltd

NovaLead Pharma Pvt Ltd

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH

Pressure Ulcers - Drug Profiles

AG-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-Decorin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EscharEx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IZN-6D4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Statmicoll - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Pressure Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pressure Ulcers - Dormant Projects

Pressure Ulcers - Discontinued Products

Pressure Ulcers - Product Development Milestones

Featured News & Press Releases

Aug 24, 2016: MediWound's EscharEx to be Featured at International Society for Burn Injuries

Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results

Sep 22, 2008: RegeneRx/Sigma-Tau Completes Patient Enrollment Of Second Phase II Clinical Trial With RGN-137

Aug 20, 2008: RegeneRx Completes Patient Enrollment Of First Phase II Clinical Trial

Nov 02, 2004: RegeneRx Gets Cleared To Initiate Phase II Clinical Trial With Tß4 For Chronic Pressure Ulcers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Pressure Ulcers, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pressure Ulcers - Pipeline by EyeGene Inc, H2

Pressure Ulcers - Pipeline by Izun Pharmaceuticals Corp, H2

Pressure Ulcers - Pipeline by MediWound Ltd, H2

Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H2

Pressure Ulcers - Pipeline by RegeneRx Biopharmaceuticals Inc, H2

Pressure Ulcers - Pipeline by RMB-Research GmbH, H2

Pressure Ulcers - Dormant Projects, H2

Pressure Ulcers - Discontinued Products, H2

List of Figures:

Number of Products under Development for Pressure Ulcers, H2

Number of Products under Development by Companies, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • EyeGene Inc
  • Izun Pharmaceuticals Corp
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • RegeneRx Biopharmaceuticals Inc
  • RMB-Research GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll